Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

By B. Maron, W. Shen, Mark S. Link, Andrew E Epstein, A. Almquist, J. Daubert, G. Bardy, S. Favale, R. Rea, G. Boriani and 5 more. New England Journal of Medicine, 2000

987 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/449101cdc612b0b0d1ce84a8e148e476c6e73646

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. B. Maron
2. Steve R. Ommen
3. M. Maron
4. P. Spirito
5. C. Semsarian
6. Iacopo Olivotto
7. J. Udelson
8. Mark S. Link

Citations in the corpus

• Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. (2002, neutral): “patients with hypertrophic cardiomyopathy (HCM) (1).”
• Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy (2014, methodology): “Stored intracardiac electrograms were analyzed independently at each center by expert electrophysiologists blinded to CMR results; ICD discharges were characterized as appropriate if triggered by ventricular fibrillation or rapid ventricular tachycardia (rate, ≥180 bpm).(7,10)”
• Hypertrophic cardiomyopathy: a systematic review. (2002, background): “Appropriate device interventions occurred at 11% annually for secondary prevention (implant following cardiac arrest) and 5% annually for primary prevention (implant based on risk factors), usually in patients with no or only mild prior symptoms.(98) Patients receiving appropriate shocks were young ”
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G (2003, background): “Indeed, ventricular arrhythmias are an important clinical feature in adults with HCM.”
• Task Force on Sudden Cardiac Death of the European Society of Cardiology. (2001, background): “SCD prevention with the ICD is most strongly recommended for patients surviving prior cardiac arrest and for primary prevention in patients with two or more risk factors (identified during non-invasive risk stratification) in whom annual SCD rates are 3–6% or more([273,274,285,287]).”